


Glucokinase activator 1

Cat. No.:	HY-101788
CAS No.:	1328987-85-4
Molecular Formula:	C ₂₇ H ₂₀ F ₂ N ₂ O ₇ S ₂
Molecular Weight:	586.58
Target:	Glucokinase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Glucokinase activator 1 is a liver-directed glucokinase activator with an EC ₅₀ of 34 nM.																
IC₅₀ & Target	EC ₅₀ : 34 nM (Glucokinase) ^[1]																
In Vivo	<p>Glucokinase activator 1 (3 to 300 mg/kg, oral, 180 minutes) shows a dose dependent improvement in glucose excursion in oGTT in a DIO mouse model of T2D. The predominant liver-directed tissue distribution of Glucokinase activator 1 ensures a good safety window with respect to hypoglycemia over a 10-fold dose range^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57BL/6J mice (age 8-10 weeks; 25±5 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 or 3 mg/kg (i.v.), 30 mg/kg (oral)</td> </tr> <tr> <td>Administration:</td> <td>I.v. or oral</td> </tr> <tr> <td>Result:</td> <td>Showed an excellent PK profile and exhibited 35- and 68- fold higher liver concentrations at 1 and 3 h time point, respectively, compared with plasma^[1].</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57BL/6J mice of 10-12 weeks^[1]</td> </tr> <tr> <td>Dosage:</td> <td>3 to 300 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral (15, 30, 60, 120 and 180 minutes)</td> </tr> <tr> <td>Result:</td> <td>Demonstrated 21% and 34% significant AUC glucose reduction at oral dose of 30 and 100 mg/kg, respectively^[1].</td> </tr> </table>	Animal Model:	Male C57BL/6J mice (age 8-10 weeks; 25±5 g) ^[1]	Dosage:	1 or 3 mg/kg (i.v.), 30 mg/kg (oral)	Administration:	I.v. or oral	Result:	Showed an excellent PK profile and exhibited 35- and 68- fold higher liver concentrations at 1 and 3 h time point, respectively, compared with plasma ^[1] .	Animal Model:	Male C57BL/6J mice of 10-12 weeks ^[1]	Dosage:	3 to 300 mg/kg	Administration:	Oral (15, 30, 60, 120 and 180 minutes)	Result:	Demonstrated 21% and 34% significant AUC glucose reduction at oral dose of 30 and 100 mg/kg, respectively ^[1] .
Animal Model:	Male C57BL/6J mice (age 8-10 weeks; 25±5 g) ^[1]																
Dosage:	1 or 3 mg/kg (i.v.), 30 mg/kg (oral)																
Administration:	I.v. or oral																
Result:	Showed an excellent PK profile and exhibited 35- and 68- fold higher liver concentrations at 1 and 3 h time point, respectively, compared with plasma ^[1] .																
Animal Model:	Male C57BL/6J mice of 10-12 weeks ^[1]																
Dosage:	3 to 300 mg/kg																
Administration:	Oral (15, 30, 60, 120 and 180 minutes)																
Result:	Demonstrated 21% and 34% significant AUC glucose reduction at oral dose of 30 and 100 mg/kg, respectively ^[1] .																

REFERENCES

[1]. Deshpande AM, et al. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia. *Eur J Med Chem.* 2017 Jun 16;133:268-286.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA